Trials / Completed
CompletedNCT01491932
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AFQ056 | AFQ056 will be supplied as oral capsules. |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2011-12-14
- Last updated
- 2020-12-23
Locations
32 sites across 10 countries: United States, Austria, Canada, France, Germany, Hungary, Italy, Slovakia, Spain, Switzerland
Source: ClinicalTrials.gov record NCT01491932. Inclusion in this directory is not an endorsement.